» Articles » PMID: 20109508

The Effect of Surface Functionalization of PLGA Nanoparticles by Heparin- or Chitosan-conjugated Pluronic on Tumor Targeting

Overview
Specialty Pharmacology
Date 2010 Jan 30
PMID 20109508
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The poly (lactide-co-glycolide) (PLGA)-based nanoparticles, coated by the heparin- or chitosan-Pluronic conjugate, were used to improve a relatively low tumor-targeting efficiency of the bare PLGA nanoparticles. The prepared nanoparticles were in the size range of 100-150nm, and the surface exposure of the functional moiety (heparin or chitosan) was confirmed by negatively or positively increased zeta potential values, respectively. The viability tests for both normal and tumor cells displayed minimal cytotoxicity of the nanoparticles. The stable surface coating, which was evident from no change in the size distribution profiles in spite of the surface charge changes in serum environment, effectively provided the desired functionalized surface that clearly enhanced the in vitro cellular uptake of the nanoparticles for both heparin and chitosan functionalization. The in vivo tumor model study, which was carried out in SCC7 tumor-bearing athymic mice, demonstrated that there was a limited, but positive effect of surface functionalization, more effective for chitosan functionalization. The accumulation of chitosan-functionalized PLGA nanoparticles in tumor was 2.4 folds higher than that of the control, PLGA nanoparticles coated with bare Pluronic, and the accumulation in liver was lower than the control. In the case of heparin functionalization, the mean value was 2.2 folds higher than that of the control, but the accumulation in liver was similar to that of the control. Therefore, the surface-functionalization by the chitosan- or heparin-conjugated Pluronic may be an effective approach for the hydrophobic nanoparticle systems aiming for the enhanced tumor imaging and therapy.

Citing Articles

Efficacy of oral insulin nanoparticles for the management of hyperglycemia in a rat model of diabetes induced with streptozotocin.

Abd-Alhussain G, Alatrakji M, Ahmed S, Fawzi H J Med Life. 2024; 17(2):217-225.

PMID: 38813352 PMC: 11131628. DOI: 10.25122/jml-2023-0355.


Novel Therapeutic Approach in PEGylated Chitosan Nanoparticles of Apigenin for the Treatment of Cancer via Oral Nanomedicine.

Mujtaba M, Alotaibi N, Alshehri S, Yusuf M, Anwer M, Rahman M Polymers (Basel). 2022; 14(20).

PMID: 36297920 PMC: 9609346. DOI: 10.3390/polym14204344.


Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates.

Seong J, Kim K Pharmaceutics. 2022; 14(7).

PMID: 35890254 PMC: 9316852. DOI: 10.3390/pharmaceutics14071358.


Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines.

El-Hammadi M, Arias J Nanomaterials (Basel). 2022; 12(3).

PMID: 35159698 PMC: 8840194. DOI: 10.3390/nano12030354.


PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery.

Sheffey V, Siew E, Tanner E, Eniola-Adefeso O Adv Healthc Mater. 2022; 11(8):e2101536.

PMID: 35032406 PMC: 9035064. DOI: 10.1002/adhm.202101536.